tom-graney_portrait

Vertex Pharma bring in new CFO, shares rise

pharmafile | September 7, 2017 | Appointment | |  Ironwood Pharmaceuticals, Vertex pharmaceuticals, biotech, drugs, pharma, pharmaceutical 

Vertex Pharmaceuticals announced the appointment of J&J veteran, Tom Graney, as Senior Vice President and Chief Financial Officer. Graney will join the company on 13 September, after departing Ironwood Pharmaceuticals for the role. The esteem with which Graney is held saw shares immediately rise on the release of the news for Vertex by 1.2% and fall for Ironwood by close to 2%.

At Ironwood, he held the role of CFO and Senior Vice President of Finance and Corporate Strategy. Prior to this, he held numerous roles across the Johnson & Johnson’s franchise in his 20-year career at the company; he held roles at the pharma giant that include being the Finance Director for Janssen in the UK, Ireland and Africa. He was also CFO for the North American arm of the Janssen business, rising to VP of Finance and the Global Supply Chain at the overall J&J business.

“I am thrilled to take on this important role with Vertex, a company that I have long admired for its unwavering commitment to patients and to discovering, developing and commercializing transformative medicines for people with serious and life-threatening diseases,” said Graney.

Advertisement

“As Vertex continues its evolution to be a leading global biotech, it is critical that we continue to build a strong and experienced leadership team,” said Ian Smith, Executive Vice President and Chief Operating Officer of Vertex. “Tom has the ideal blend of financial acumen, leadership skills, and industry experience that will be important as Vertex grows and expands as a global company.”

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …

The Gateway to Local Adoption Series

Latest content